Autolus Therapeutics (AUTL) Share-based Compensation (IS) (2018 - 2019)

Autolus Therapeutics posted quarterly Share-based Compensation (IS) of $16.2 million for Q2 2019, up 337.14% year-on-year from $3.7 million in Q2 2018, and up 337.14% on a QoQ basis from $3.7 million in Q2 2018.

Autolus Therapeutics (AUTL) has 2 years of Share-based Compensation (IS) data on file, last reported at $16.2 million in Q2 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Stock Comp. (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - 1.45 Mn
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn 14.90 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn -
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn -
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn -
10 Autolus Therapeutics - - -1.04 Mn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2019 16.23 Mn
Jun 30, 2019 16.23 Mn
Jun 30, 2018 3.71 Mn
Jun 30, 2018 3.71 Mn